Katherine M. Sandstrom, a member of Janus Living, Inc.’s board of directors, purchased 13,500 shares of the company’s Class A-1 Common Stock at $20.00 per share, a transaction valued at $270,000, the company disclosed in a Form 4 filed with the Securities and Exchange Commission. The filing lists the trade date as March 23, 2026.
Janus Living’s shares are currently quoted at $23.75, which equates to an immediate paper gain of nearly 19% on the price Sandstrom paid. The filing notes the stock is trading near its 52-week high of $24.36. An InvestingPro Tip included with the filing indicates there are four additional exclusive tips available to subscribers.
In addition to the purchased shares, the Form 4 shows Sandstrom received equity awards at no cost: 2,500 shares of Class A-1 Common Stock issued as vested shares in connection with the company’s initial public offering, and 5,000 shares issued as restricted stock units (RSUs) representing annual equity compensation for her service as a director.
Those equity movements coincide with a period of notable financing activity for Janus Living. The company has closed a $600 million credit facility intended to support its growth strategy. That package comprises a $500 million unsecured revolving credit line and a $100 million unsecured delayed-draw term loan, with maturity dates in March 2030 and March 2031, respectively.
Janus Living also completed its initial public offering during this period. The IPO priced at $20.00 per share, at the top of the marketed range, and raised a total of $840 million. That amount exceeded the company’s initial target of $740 million. The shares had been offered in a range of $18.00 to $20.00 per share.
Together, the insider purchase, the equity grants reported for Sandstrom, the new credit facility, and the IPO fundraising reflect concentrated corporate financing and compensation actions disclosed in the company’s public filings. The SEC Form 4 documents the director’s direct purchase and the complimentary equity awards; the credit agreement and IPO pricing information detail the company’s recent capital-raising steps.
Note: The article reflects information disclosed in the company’s filings and public statements; it does not add or infer facts beyond those items.